OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
May 30, 2017 12:08 pm UTC| Business
GAITHERSBURG, Md., May 30, 2017 -- OpGen, Inc. (NASDAQ:OPGN) announced today that they will be recognized with the 2nd annual Ignaz Semmelweis Award for their commitment to safe medical care through the development of...
May 30, 2017 12:07 pm UTC| Business
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor...
May 30, 2017 12:07 pm UTC| Business
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor...
May 30, 2017 12:07 pm UTC| Business
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor...
May 30, 2017 12:07 pm UTC| Business
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor...
May 30, 2017 12:07 pm UTC| Business
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor...
May 30, 2017 12:07 pm UTC| Business
RESEARCH TRIANGLE PARK, N.C., May 30, 2017 -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor...